Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. (Q37061964)

18 August 2017

1 reference

title

Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. (English)

1 reference

stem cell transplantation

18 August 2017

main subject

1 reference

C F Craddock

1 reference

18 August 2017

language of work or name

English

0 references

publication date

21 January 2008

1 reference

Bone Marrow Transplantation

18 August 2017

published in

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

page(s)

415-423

1 reference

EBMT activity survey 2004 and changes in disease indication over the past 15 years

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Treatment of older patients with AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Genetics of myeloid malignancies: pathogenetic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Prognostically useful gene-expression profiles in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Drug therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Preferential induction of apoptosis for primary human leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

mTOR regulates cell survival after etoposide treatment in primary AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Therapeutic and diagnostic applications of minor histocompatibility antigen HA-1 and HA-2 disparities in allogeneic hematopoietic stem cell transplantation: a survey of different populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an adult treater's view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first compl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Gene expression profiling in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

A Prospective Multicenter Trial of Peripheral Blood Stem Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remission Using Fludarabine-Cyclophosphamide Reduced Intensity Conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705975

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705975

1 reference

Dimensions Publication ID

18 August 2017

1040868100

0 references

Fatcat ID

release_o3eugn3pcva6fnzeygp2szw2ie

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/o3eugn3pcva6fnzeygp2szw2ie

24 November 2022

mapped directly with Wikidata item

1 reference